openPR Logo
Press release

Anemia Drugs Market Globally Maintain a CAGR of 8.4% by 2023 - GlycoMimetics Inc., Regen biopharma Inc., Bayer AG, Acceleron Pharma, Eli Lilly and Company, etc

01-24-2019 07:51 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Market Research Future

Anemia Drugs Market

Anemia Drugs Market

The Global Anemia Drugs Market is growing with the sound pace. According to a recent study report published by the Market Research Future, the global anemia drugs market is booming and is expected to gain prominence over the forecast period growing rapidly .The market is forecasted to demonstrate a spectacular growth by 2022, surpassing its previous growth records in terms of value with a sound CAGR during the anticipated period (2017 – 2022).

The global market for anemia drugs is growing at a good rate. The market driving factors are growth of geriatric population, increasing awareness, increasing focus of social healthcare on women health and particularly anemia, rise in accidents and cancer, rise in other risk factors such as diabetes, modern lifestyle induced stress, poor nutritional habits, rise in lactating and pregnant women in developing regions, intestinal infections etc.

To Get Sample Report visit https://www.marketresearchfuture.com/sample_request/2499

The market constraints are poor absorption of drugs especially intravenous iron and the side effects associated with the treatment. Better nutrition due to rising per capita income is also a market limiting factor for anemic drugs.

The Anemia Drugs Market is expected to be around US$21.4 billion and is expected to grow at a CAGR of 8.4% to reach US$34.7 billion by the end of forecast period.

Key Players for Global Anemia Drugs Market

Amgen Inc., GlaxoSmithKline plc, Bluebird bio, Biocon, GlycoMimetics Inc., Regen biopharma Inc., Bayer AG, Acceleron Pharma, Eli Lilly and company are some of the prominent players at the forefront of competition in the global anemia drugs market and are profiled in MRFR Analysis.

Characterized by the presence of several well-established and small players, the global anemia drugs market appears to be highly competitive and fragmented. International players who are increasingly expanding their footprint in the developing economies, makes it difficult for regional vendors to compete with them, especially in terms of features such as product portfolios, quality, and pricing. The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The intense competition prevalent in the market dictates the consolidation among marketers.

Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.

In April-2017, Amgen Inc. expanded their commercial collaboration with Novartis for erenumab, which is being investigated for the prevention of migraine. This expanded commercial collaboration was built on a global neuroscience collaboration in Alzheimer's disease and migraine established in 2015 between Novartis and Amgen. This expanded collaboration leveraged Novartis' strong and established presence in neuroscience to more effectively reach people with migraine.

In December-2015, GlaxoSmithKline plc. announced that its global HIV business, ViiV Healthcare, has reached two separate agreements with Bristol-Myers Squibb, to acquire its late-stage HIV R&D assets; and to acquire Bristol-Myers Squibb’s portfolio of preclinical and discovery stage HIV research assets.

In October-2016, Elanco U.S., Inc., a subsidiary of Eli Lilly and Company acquired Boehringer Ingelheim Vetmedica, Inc.'s (BIVI) U.S. feline, canine and rabies vaccines portfolio - as well as a fully integrated manufacturing and R&D site - for USD 885 million, including the estimated cost of acquired inventory.

Segments for Global Anemia Drugs Market

Global anemia drugs market has been segmented on the basis of anemia type which comprises iron deficiency anemia, sickle cell anemia, aplastic anemia, hemolytic anemia pernicious anemia and others. On the basis of route of administration; market is segmented into oral and injectable. On the basis of gender; market is segmented into male and female. On the basis of product type; market is segmented into biologics and non-biologics. On the basis of end users; market is segmented into hospitals, self-administered and others.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/anemia-drugs-market-2499

Regional Analysis for Global Anemia Drugs Market

On the regional backgrounds the Americas leads the global market for anemia drugs owing to huge patient population, increasing healthcare expenditures and presence of the developed economies like U.S. and Canada within the region. Following, the same trends Europe is second in the market. The Asia Pacific region is the fastest growing region due to the developing economies like India and China. Middle East and Africa have the least market share, especially due to the presence of poor economies within the African region. Moreover, stringent government policies within the region are restraining the market growth within the region. On the hand, Middle East leads the regional market due to the presence of developed economies like Kuwait, Qatar, and others within the region and rising healthcare expenses.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Hadapsar, Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Anemia Drugs Market Globally Maintain a CAGR of 8.4% by 2023 - GlycoMimetics Inc., Regen biopharma Inc., Bayer AG, Acceleron Pharma, Eli Lilly and Company, etc here

News-ID: 1528352 • Views:

More Releases from Market Research Future

9-Decanoic Acid Methyl Ester Market Poised for Strong 6.59% CAGR Growth Through 2035
9-Decanoic Acid Methyl Ester Market Poised for Strong 6.59% CAGR Growth Through …
The 9-decanoic acid methyl ester market is a growing sector driven by the increasing demand for bio-based and sustainable chemical products across various industries. With its unique properties, it finds application in flavors and fragrances, pharmaceuticals, personal care, and as a chemical intermediate. The market is projected to expand significantly in the coming years. Market Overview and Size The global 9-decanoic acid methyl ester market was valued at USD 230.0 million in
Washable Marker Market Poised for 3.54% CAGR Growth During 2024-2032
Washable Marker Market Poised for 3.54% CAGR Growth During 2024-2032
The washable marker market is a dynamic and growing segment within the broader stationery and art supplies industry. Driven by a blend of consumer demands for safety, convenience, and sustainability, the market is experiencing consistent expansion, particularly within the education and home-use sectors. While faced with some challenges, the industry's future looks promising, propelled by product innovation and evolving consumer trends. Get Sample @ https://www.marketresearchfuture.com/sample_request/41217 Market Size and Growth The global washable
Phone Car Mounts Market to Reach USD 7.37 Billion by 2034, Growing at 6.47% CAGR
Phone Car Mounts Market to Reach USD 7.37 Billion by 2034, Growing at 6.47% CAGR
The phone car mounts market, a critical sub-segment of the broader automotive accessories industry, is experiencing robust growth driven by a convergence of technological advancements, evolving consumer behavior, and increasingly stringent road safety regulations. As smartphones become indispensable for navigation, communication, and in-car entertainment, the demand for secure and convenient hands-free solutions continues to escalate. The global phone car mounts market was valued at USD 3.93 billion in 2024 and
Intravenous (IV) Solution Market Set to Grow to USD 26.60 Billion at 7.70% CAGR by 2032
Intravenous (IV) Solution Market Set to Grow to USD 26.60 Billion at 7.70% CAGR …
Market Overview: The Intravenous (IV) Solution Market is estimated to be valued at USD 13.9 billion in 2023 and is projected to reach USD 26.60 billion by 2032, expanding at a compound annual growth rate (CAGR) of 7.70% from 2024 to 2031. The market growth is attributed to the rising prevalence of chronic diseases, growing hospitalization rates, and increasing surgical procedures that require IV fluid administration. Intravenous solutions are critical

All 5 Releases


More Releases for Anemia

Rising Cancer And Anemia Cases Propel Growth In Chemotherapy-Induced Anemia Mark …
The Chemotherapy-Induced Anemia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Chemotherapy-Induced Anemia Market Size During the Forecast Period? The Chemotherapy-Induced Anemia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This
Iron Deficiency Anemia Market Analysis 2034 | Iron Deficiency Anemia Therapies, …
As per DelveInsight, the Iron Deficiency Anemia Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies and the increase in the incident population of Iron Deficiency Anemia in the 7MM. DelveInsight's "Iron Deficiency Anemia Market Insights, Epidemiology, and Market Forecast 2034 [https://www.delveinsight.com/report-store/iron-deficiency-anemia-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Iron Deficiency Anemia market size,
Aplastic Anemia Treatment Market - Shaping the Future of Aplastic Anemia Health: …
Newark, New Castle, USA: The "Aplastic Anemia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Aplastic Anemia Treatment Market: https://www.growthplusreports.com/report/aplastic-anemia-treatment-market/8435 This latest report researches the industry structure,
Anemia Drugs Market 2018 Grow at CAGR of 8.4% to Reach USD 34.7 Billion | By Uni …
Market Research Future Published a Prime research Report on “Global Anemia Drugs Market Research Report - Forecast to 2022” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2022 Global Anemia Drugs Market - Segments Global anemia drugs market has been segmented on the basis of anemia type which comprises iron deficiency anemia, sickle cell anemia, aplastic anemia, hemolytic anemia pernicious anemia and others. On the basis of route of administration;
Anemia in Chronic Kidney Disease (Renal Anemia) - Industry Analysis, Trends, and …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Anemia in Chronic Kidney Disease Pipeline Review, H1 2017” to its report offerings. The report provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline landscape. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1196648 Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2017,
Global Anemia in Chronic Kidney Disease (Renal Anemia) Clinical Trials Market Re …
Market Research Hub's clinical trial report, Global Anemia in Chronic Kidney Disease (Renal Anemia) Clinical Trials Review, H1, 2017, provides an overview of Anemia in Chronic Kidney Disease (Renal Anemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Anemia in Chronic Kidney Disease (Renal Anemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Request